- Blood plasma-derived products are essential for treating a wide range of life-threatening conditions, including immune deficiencies, hemophilia, and neurological and autoimmune disorders. In Thailand, the growing burden of chronic diseases, increasing healthcare access, and government efforts to strengthen plasma collection and self-sufficiency are key factors driving the market expansion
- The rising demand for plasma-derived therapies is fueled by an aging population, increasing prevalence of rare and chronic conditions, and the expanding application of immunoglobulin and coagulation factors in critical care and post-transplant treatments.
- Hyperimmune globulin is expected to dominate the Thailand blood plasma market with a market share of 32.8.5 in 2024, driven by its specialized use in emerging infectious diseases such as COVID-19 and dengue, both of which are prevalent in the region. The government’s interest in emergency preparedness and immunization programs further supports the segment’s growth
